Adelaide's Royal Adelaide Hospital haematology department manages ITP patients across South Australia requiring long-term TPO-RA therapy. Eltromag 25mg provides the same clinical benefit as Promacta and Revolade at significantly reduced cost for Adelaide patients seeking private access or facing PBS coverage gaps.
Eltrombopag's ability to raise platelet counts without broadly suppressing the immune system makes it well-suited for long-term ITP management in Adelaide's working-age adult population who need safe, well-tolerated therapy compatible with full-time employment and normal activities.
Eltrombopag's ability to raise platelet counts without broadly suppressing the immune system makes it well-suited for long-term ITP management in Adelaide's working-age adult population who need safe, well-tolerated therapy compatible with full-time employment and normal activities.
What is the difference between primary and secondary ITP, and does Eltromag treat both?Primary (idiopathic) ITP has no identifiable underlying cause — the autoimmune platelet destruction occurs spontaneously, likely triggered by a complex interaction between genetic predisposition and possibly a prior infection. Secondary ITP occurs as a consequence of another identifiable condition — such as lupus, antiphospholipid syndrome, HIV infection, Hepatitis C, or certain medications. Eltrombopag (Eltromag) can be used in both primary and secondary ITP to boost platelet production, but for secondary ITP, treating or addressing the underlying cause is equally important alongside Eltrombopag — for example, treating underlying HIV or stopping a causative drug. Your haematologist will assess which type you have before deciding on the treatment plan.
